Subcutaneous · GIP agonist
Macupatide
7 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
7
Active
3
Recruiting
2
Completed
4
Sites
93
Countries
6
Endpoints
37
Composite endpoints
6
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
4
Phase 2
3
Trials by status
Not yet recruiting
1
Recruiting
2
Completed
4
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
14
Glycemic / diabetes
12
Weight & body composition
8
Other (unclassified)
3
Most-measured metrics
Top 20 metrics across this asset's endpoints
Treatment-emergent AEs (any)Safety/PK
4
CmaxSafety/PK
4
AUC₀–∞Safety/PK
4
Body weight, % changeWeight
3
Postprandial glucoseGlycemic
2
HbA1c, changeGlycemic
2
BMI, changeWeight
2
HOMA-IR (insulin sensitivity)Glycemic
1
Serious AEs (any)Safety/PK
1
TmaxSafety/PK
1
Body weight, absolute change (kg)Weight
1
≥5% weight-loss respondersWeight
1
≥10% weight-loss respondersWeight
1
Fasting glucose, changeGlycemic
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
7 of 7